COCONUT GROVE, Fla.--(BUSINESS WIRE)--Dec. 14, 2004--AlphaNet, Inc., a not-for-profit organization founded to improve the health of individuals with alpha-1 antitrypsin deficiency (Alpha-1), has followed the proposed divestiture of Bayer AG’s plasma products business with great interest. Today it was announced that an agreement has been signed between NPS BioTherapeutics, Inc. and Bayer AG. AlphaNet believes that the Alpha-1 community will continue to receive the high level of commitment that has been the hallmark of its relationship with Bayer over the past five years.
